Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials

The Lancet Oncology

Volumn 17, Issue 8, 2016, Pages 1037-1039

  Ascierto, Paolo A ^a   Long, Georgina V ^b,c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Ryde and North Shore Hospitals   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COBIMETINIB; DABRAFENIB; DACARBAZINE; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE; NIVOLUMAB; PEMBROLIZUMAB; TALIMOGENE LAHERPAREPVEC; TRAMETINIB; VEMURAFENIB; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADVANCED CANCER; CANCER CONTROL; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; EVIDENCE BASED MEDICINE; HUMAN; MELANOMA; NOTE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLID TUMOR; SURVIVAL TIME; TREATMENT RESPONSE; BIOASSAY; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; METHODOLOGY; MOLECULARLY TARGETED THERAPY; MORTALITY; ONCOLYTIC VIROTHERAPY; PATHOLOGY; PROCEDURES; SKIN TUMOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY; ONCOLYTIC VIROTHERAPY; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84977472495     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30017-1     Document Type: Note

References (12)

1. 1 Hodi, FS, O'Day, SJ, McDermott, DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
2. 2 Chapman, PB, Hauschild, A, Robert, C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364 (2011), 2507–2516.
3. 3 Robert, C, Long, GV, Brady, B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372 (2015), 320–330.
4. 4 Long, GV, Stroyakovskiy, D, Gogas, H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386 (2015), 444–451.
5. 5 Robert, C, Schachter, J, Long, GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372 (2015), 2521–2532.
6. 6 Larkin, J, Chiarion-Sileni, V, Gonzalez, R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
7. 7 Andtbacka, RH, Kaufman, HL, Collichio, F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33 (2015), 2780–2808.
8. 8 Larkin, J, Ascierto, PA, Dréno, B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371 (2014), 1867–1876.
9. 9 Flaherty, KT, Hennig, M, Lee, SJ, et al. Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. Lancet Oncol 15 (2014), 297–304.
10. 10 Wolchok, JD, Hoos, A, O'Day, S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15 (2009), 7412–7420.
11. 11 Korn, EL, Liu, PY, Lee, SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26 (2008), 527–534.
12. 12 Schadendorf, D, Hodi, FS, Robert, C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33 (2015), 1889–1894.